

[illegible]

@PFDesktop\.:ODMA\MHODMA\HBSR05;iManage;639282;1

PTO-1449 REPRODUCED

ATTORNEY DOCKET NO.  
3022.1004-000APPLICATION NO.  
10/088,677SECOND SUPPLEMENTAL INFORMATION  
DISCLOSURE STATEMENT IN AN APPLICATION

July 25, 2006

FIRST NAMED INVENTOR  
Joerg SchneiderFILING DATE  
May 31, 2002EXAMINER  
Robert A. ZemanCONFIRMATION NO.  
4825GROUP  
1645

JUL 31 2006

(Use several sheets if necessary)

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

/RAZ/	C1	Anderson, <i>et al.</i> , "Enhanced CD8 T Cell Response and Protective Efficacy Against Malaria Using Recombinant Fowlpox Virus In Heterologous Prime/Boost Immunisation Regimes," Abstract, <i>Immunology 101</i> (Supplement 1):32 (2000).
/RAZ/	C2	Berkner, K.L., "Development of Adenovirus Vectors For The Expression of Heterologous Genes," <i>BioTechniques</i> , 6(7): 616-629, (1988).
/RAZ/	C3	Buge, S.L., <i>et al.</i> , "Factors Associated With Slow Disease Progression in Macaques Immunized With an Adenovirus-Simian Immunodeficiency Virus (SIV) Envelope Priming-gp120 Boosting Regimen and Challenged Vaginally With SIVmac251," <i>Journal of Virology</i> , 73(9):7430-7440, (1999).
/RAZ/	C4	Chamberlain, R.S., Poster Presentation presented at the Meeting of the American Association of Cancer Research, April 20 <sup>th</sup> through April 24 <sup>th</sup> , 1996.
/RAZ/	C5	Chamberlain, R.S., <i>et al.</i> , "Use of Multiple Vaccination Vectors for the Generation of CTL Against a Model Tumor Antigen," <i>Proceedings of the Annual Meeting of the American Association for Cancer Research</i> (Washington, April 20-24, 1996, 37, Abstract No. 3263).
/RAZ/	C6	E-mail from American Society for Microbiology re: Date of Disclosure of Buge's Document.
/RAZ/	C7	Hanke, T., <i>et al.</i> , "Enhancement of MHC Class I-Restricted Peptide-Specific T Cell Induction by a DNA Prime/MVA Boost Vaccination Regime," <i>Vaccine</i> , 16(5):439-445, (1998).
/RAZ/	C8	Hodge, J.W., <i>et al.</i> , "Diversified Prime and Boost Protocols Using Recombinant Vaccinia Virus and Recombinant Non-Replicating Avian Pox Virus to Enhance T-Cell Immunity and Antitumor Responses," <i>Vaccine 15</i> (6/7):759-768 (April/May 1997).
/RAZ/	C9	Irvine, K.R., <i>et al.</i> , "Enhancing Efficacy of Recombinant Anticancer Vaccines With Prime/Boost Regimens That Use Two Different Vectors," <i>Journal of the National Cancer Institute</i> , 89(21):1595-1601, (1997).
/RAZ/	C10	Kent, S. J., <i>et al.</i> , "Enhanced T-Cell Immunogenicity and Protective Efficacy of a Human Immunodeficiency Virus Type 1 Vaccine Regimen Consisting of Consecutive Priming with DNA and Boosting with Recombinant Fowlpox Virus," <i>J. Virol.</i> 72(12):10180-10188 (1998).
/RAZ/	C11	Li, Shengqiang, <i>et al.</i> , "Priming With Recombinant Influenza Virus Followed By Administration of Recombinant Vaccinia Virus Induces CD8 <sup>+</sup> T-Cell-Mediated Protective Immunity against Malaria," <i>Proc. Natl. Acad. Sci. USA</i> 90(11):5214-5218 (June 1993).

EXAMINER

DATE CONSIDERED

PTO-1449 REPRODUCED		ATTORNEY DOCKET NO. 3022.1004-000		APPLICATION NO. 10/088,677	
<b>SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION</b>  July 25, 2006 (Use several sheets if necessary)				FIRST NAMED INVENTOR Joerg Schneider	
				FILING DATE May 31, 2002	
EXAMINER Robert A. Zeman				CONFIRMATION NO. 4825	GROUP 1645

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
/RAZ/	C12	McShane, H., <i>et al.</i> , "Enhanced Immunogenicity of CD4 <sup>+</sup> T-Cell Responses and Protective Efficacy of a DNA-Modified Vaccinia Virus Ankara Prime-Boost Vaccination Regimen for Murine Tuberculosis," <i>Infect. Imm.</i> 69(2):681-686 (2001).
/RAZ/	C13	Notice of Opposition to a European Patent. Patent No.: EP 1214416B1. Opponent: Merck & Co., Inc.
/RAZ/	C14	Notice of Opposition to a European Patent. Patent No.: EP 1214416B1. Opponent: Crucell Holland B.V.
/RAZ/	C15	Notice of Opposition to a European Patent. Patent No.: EP 1214416. Opponent: Transgene S.A. (English translation attached)
/RAZ/	C16	Plebanski, M., <i>et al.</i> , "Protection From <i>Plasmodium berghei</i> Infection By Priming and Boosting T Cells to a Single Class I-Restricted Epitope with Recombinant Carriers Suitable for Human Use," <i>Eur. J. Immunol.</i> , 28(12):4345-4355 (1998).
/RAZ/	C17	Reece, WHH, <i>et al.</i> , "A DNA/MVA Prime-Boost Vaccination Regime Induces Strong Immune Responses and Partial Protection Against <i>Plasmodium falciparum</i> in Humans," <i>Poster at the British Society for Immunology</i> (December 2001).
/RAZ/	C18	Richmond, J.F.L., <i>et al.</i> , "Screening of HIV-1 Env Glycoproteins for the Ability to Raise Neutralizing Antibody Using DNA Immunization and Recombinant Vaccinia Virus Boosting," <i>Virology</i> 230:265-274 (1997).
/RAZ/	C19	Robert-Guroff, M., <i>et al.</i> , "Vaccine Protection Against a Heterologous, Non-Syncytium-Inducing, Primary Human Immunodeficiency Virus," <i>Journal of Virology</i> , 72(12):10275-10280, (1998).
/RAZ/	C20	Robinson, H. L., <i>et al.</i> , "Neutralizing Antibody-independent Containment of Immunodeficiency Virus Challenges by DNA Priming and Recombinant Pox Virus Booster Immunizations," <i>Nature Medicine</i> 5(5):526-534 (1999).
/RAZ/	C21	Rodrigues, E.G., <i>et al.</i> , "Efficient Induction of Protective Anti-Malaria Immunity By Recombinant Adenovirus," <i>Vaccine</i> , 16(19):1812-1817, (1998).
/RAZ/	C22	Rodrigues, E.G., <i>et al.</i> , "Single Immunizing Dose of Recombinant Adenovirus Efficiently Induces CD8 <sup>+</sup> T Cell-Mediated Protective Immunity Against Malaria," <i>The Journal of Immunology</i> , 158:1268-1274, (1997).

EXAMINER	DATE CONSIDERED
----------	-----------------

**APPLICATION NO.**  
**10/088,677**

FIRST NAMED INVENTOR  
Joerg Schneider

**FILING DATE**  
**May 31, 2002**

**July 25, 2006**

**EXAMINER**  
**Robert A. Zeman**

CONFIRMATION NO.  
4825

**GROUP  
1645**

(Use several sheets if necessary)

## FOREIGN PATENT DOCUMENTS


[illegible]

**EXAMINER**

DATE. CONSIDERED

05/29/2007

Sheet 5 of 5

PTO-1449 REPRODUCED		ATTORNEY DOCKET NO. 3022.1004-000		APPLICATION NO. 10/088,677	
SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION				FIRST NAMED INVENTOR Joerg Schneider	
				FILING DATE May 31, 2002	
 July 25, 2006 (Use several sheets if necessary)				EXAMINER Robert A. Zeman	
				CONFIRMATION NO. 4825	
				GROUP 1645	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
/RAZI/	C23	Schneider, J., <i>et al.</i> , "Induction of CD8* T Cells Using Heterologous Prime-Boost Immunisation Strategies," <i>Immunology Reviews</i> , 170:29-38, (1999).
/RAZI/	C24	Schneider, J., <i>et al.</i> , "A Prime-Boost Immunisation Regimen Using DNA Followed By Recombinant Modified Vaccinia Virus Ankara Induces Strong Cellular Immune Responses Against the <i>Plasmodium falciparum</i> TRAP Antigen In Chimpanzees," <i>Vaccine</i> , 19(32):4595-4602 (2001).
/RAZI/	C25	Shah, K.V. and Howley, P.M., "Papillomaviruses," <i>Fields Virology, Third Edition, Chapter 66</i> , pp. 2077-2109, (1996).
/RAZI/	C26	The Chamberlain Declaration cited in the opposition proceedings of European Patent Application No. EP0979284.
/RAZI/	C27	The Gritz Declaration cited in the opposition proceedings of European Patent Application No. EP0979284.
/RAZI/	C28	The Schlom Declaration cited in the opposition proceedings of European Patent Application No. EP0979284.
/RAZI/	C29	Timofeev, A.V., <i>et al.</i> , "Immunological Basis For Protection In A Murine Model of Tick-Borne Encephalitis By a Recombinant Adenovirus Carrying the Gene Encoding the NS1 Non-Structural Protein," <i>Journal of General Virology</i> , 79:689-695, (1998).
/RAZI/	C30	Timofeyev, A.V., <i>et al.</i> , "Recombinant Adenovirus Expressing The NS1 Nonstructural Protein of Tick-Borne Encephalitis Virus: Characteristics of Immunological Basis of Antiviral Effect," <i>Vopr. Virusol.</i> 42:219-222, (1997).
/RAZI/	C31	Xiang, Z.Q., <i>et al.</i> , "Induction of Genital Immunity by DNA Priming and Intranasal Booster Immunization With a Replication-Defective Adenoviral Recombinant," <i>The Journal of Immunology</i> , 162: 6716-6723, (1999).

EXAMINER /Robert Zeman/	DATE CONSIDERED 05/29/2007
----------------------------	-------------------------------

PTO-1449 REPRODUCED

ATTORNEY DOCKET NO.  
3022.1004-000

APPLICATION NO.  
10/088,677

**FOURTH SUPPLEMENTAL  
INFORMATION DISCLOSURE STATEMENT  
IN AN APPLICATION**

**September 26, 2006**

(Use several sheets if necessary)

FIRST NAMED INVENTOR  
Joerg Schneider

371(C) DATE  
May 31, 2002

EXAMINER  
Robert A. Zeman

CONFIRMATION NO.  
4825

**GROUP  
1645**

U.S. PATENT DOCUMENTS

[illegible]

EXAMINER

DATE CONSIDERED

[illegible]

EXAMINER	DATE CONSIDERED
----------	-----------------

PTO-1449 REPRODUCED  <b>FOURTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION</b>  September 26, 2006  (Use several sheets if necessary)	ATTORNEY DOCKET NO. 3022.1004-000		APPLICATION NO. 10/088,677	
	FIRST NAMED INVENTOR Joerg Schneider		371(C) DATE May 31, 2002	
	EXAMINER Robert A. Zeman	CONFIRMATION NO. 4825	GROUP 1645	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
26	C146	Ahlers, J.D., <i>et al.</i> , "Cytokine-in-Adjuvant Steering of the Immune Response Phenotype to HIV-1 Vaccine Constructs," <i>J. Immunol.</i> 158(8):3947-3958 (1997).
	C147	Allen, T.M. and Watkins, D.I., SIV and SHIV CTL Epitopes Identified in Macaques [online], December 1998. Retrieved from the Internet <URL:http://hiv-web.lanl.gov/content/hiv-db/COMPENDIUM/1998/III/Allen98.pdf>.
	C148	An, L.-L., and Whitton, J.L., "A Multivalent Minigene Vaccine, Containing B-Cell, Cytotoxic T-Lymphocyte, and T <sub>H</sub> Epitopes from Several Microbes, Induces Appropriate Responses In Vivo and Confers Protection against More than One Pathogen," <i>J. Virol.</i> 71(3): 2292-2302 (1997).
	C149	Austyn, J.M. and Wood, K.J., "An Overview of Immune Responses," In <i>Principles of Cellular and Molecular Immunology</i> , (NY: Oxford University Press Inc.), pp. 42-44 (1993).
	C150	Bakker, A.B.H., <i>et al.</i> , "Identification of a Novel Peptide Derived from the Melanocyte-Specific GP100 Antigen as the Dominant Epitope Recognized by an HLA-A2.1-Restricted Anti-Melanoma CTL Line," <i>Int. J. Cancer</i> , 62: 97-102 (1995).
	C151	Bergmann, C.C., <i>et al.</i> , "Flanking Residues Alter Antigenicity and Immunogenicity of Multi-Unit CTL Epitopes," <i>J. Immunol.</i> 157(8): 3242-3249 (1996).
	C152	Bukowski, J.F., <i>et al.</i> , "Natural Killer Cell Depletion Enhances Virus Synthesis and Virus-Induced Hepatitis In Vivo," <i>J. Immunol.</i> 131(3): 1531-1538 (1983).
	C153	Casares, N., <i>et al.</i> , "CD4 <sup>+</sup> /CD25 <sup>+</sup> Regulatory Cells Inhibit Activation of Tumor-Primed CD4 <sup>+</sup> T Cells with IFN- $\gamma$ -Dependent Antiangiogenic Activity, as well as Long-Lasting Tumor Immunity Elicited by Peptide Vaccination," <i>J. Immunol.</i> 171(11): 5931-5939 (2003).
	C154	Cox, W.I., <i>et al.</i> , "Induction of Cytotoxic T Lymphocytes by Recombinant Canarypox (ALVAC) and Attenuated Vaccinia (NYVAC) Viruses Expressing the HIV-1 Envelope Glycoprotein," <i>Virology</i> , 195: 845-850 (1993).
	C155	Egan, M.A., <i>et al.</i> , "Use of Major Histocompatibility Complex Class I/Peptide/ $\beta$ 2M Tetramers To Quantitate CD8 <sup>+</sup> Cytotoxic T Lymphocytes Specific for Dominant and Nondominant Viral Epitopes in Simian-Human Immunodeficiency Virus-Infected Rhesus Monkeys," <i>J. Virol.</i> 73(7): 5466-5472 (1999).
26	C156	Eisenlohr, L.C., <i>et al.</i> , "Flanking Sequences Influence the Presentation of an Endogenously Synthesized Peptide to Cytotoxic T Lymphocytes," <i>J. Exp. Med.</i> 175: 481-487 (1992).

EXAMINER	DATE CONSIDERED
----------	-----------------



PTO-1449 REPRODUCED  <b>FOURTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION</b>  September 26, 2006  (Use several sheets if necessary)	ATTORNEY DOCKET NO. 3022.1004-000		APPLICATION NO. 10/088,677	
	FIRST NAMED INVENTOR Joerg Schneider		371(C) DATE May 31, 2002	
	EXAMINER Robert A. Zeman	CONFIRMATION NO. 4825	GROUP 1645	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
22	C157	Feng, C.G., <i>et al.</i> , "Induction of CD8 <sup>+</sup> T-lymphocyte Responses to a Secreted Antigen of <i>Mycobacterium tuberculosis</i> by an Attenuated Vaccinia Virus," <i>Immunol. Cell Biol.</i> 79: 569-575 (2001).
	C158	Gherardi, M.M., <i>et al.</i> , "Prime Boost Immunization Schedules Based on Influenza Virus and Vaccinia Virus Vectors Potentiate Cellular Immune Responses Against Human Immunodeficiency Virus Env Protein Systemically and in the Genitoretal Draining Lymph Nodes," <i>J. Virol.</i> 77(12): 7048-7057 (2003).
	C159	Gilbert, S.C., <i>et al.</i> , "DNA Immunisation of Mice with <i>Plasmodium berghei</i> Antigens: Use of Whole Antigens or Multi-epitope Strings, Boosting with Vaccinia and Protection Against Challenge," <i>Immunol. Lett.</i> , 56/1-3: 28 (1997) (Abstract No. 0.4.05.7).
	C160	Gönczöl, E., <i>et al.</i> , "Preclinical Evaluation of an ALVAC (canarypox)-human Cytomegalovirus Glycoprotein B Vaccine Candidate," <i>Vaccine</i> , 13(12): 1080-1085 (1995).
	C161	Hanke, T., <i>et al.</i> , "DNA and MVA-based Multi-CTL Epitope Vaccines for HIV and <i>Plasmodium falciparum</i> : Immunogenicity in Mice and Macaques," <i>Immunol. Lett.</i> , 56/1-3: 291 (1997) (Abstract No. P.4.01.22).
	C162	Hu, S.-L., <i>et al.</i> , "Protection of Macaques Against SIV Infection by Subunit Vaccines of SIV Envelope Glycoprotein gp160," <i>Science</i> , 255: 456-459 (1992).
	C163	Hunter, C.A., "How are NK Cell Responses Regulated During Infection?," <i>Experimental Parasitology</i> , 84: 444-448 (1996).
	C164	Janeway, C.A., <i>et al.</i> , "General Properties of Armed Effector T Cells." In <i>Immuno Biology</i> , (NY: Garland Publishing) p. 319 (2001).
	C165	Konishi, E., <i>et al.</i> , "Induction of Japanese Encephalitis Virus-specific Cytotoxic T Lymphocytes in Humans by Poxvirus-based JE Vaccine Candidates," <i>Vaccine</i> , 16(8): 842-849 (1998).
	C166	Konishi, E., <i>et al.</i> , "Poxvirus-Based Japanese Encephalitis Vaccine Candidates Induce JE Virus-Specific CD8 <sup>+</sup> Cytotoxic T Lymphocytes in Mice," <i>Virology</i> , 227: 353-360 (1997).
	C167	Kuby, J., "Cell-Mediated and Humoral Effector Responses." In <i>Immunology</i> , (NY: W. H. Freeman and Company) pp. 379-412 (1997).
22	C168	Linnemeyer, P.A., The Immune System - An Overview [online] November 1993 [retrieved on 2006-04-12]. Retrieved from the Internet <URL:http://www.thebody.com/step/immune.html>.

EXAMINER	DATE CONSIDERED
----------	-----------------


PTO-1449 REPRODUCED  <b>FOURTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION</b>  September 26, 2006  (Use several sheets if necessary)	ATTORNEY DOCKET NO. 3022.1004-000		APPLICATION NO. 10/088,677	
	FIRST NAMED INVENTOR Joerg Schneider		371(C) DATE May 31, 2002	
	EXAMINER Robert A. Zeman	CONFIRMATION NO. 4825	GROUP 1645	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
12	C169	Malcherek, G., <i>et al.</i> , "Supermotifs Enable Natural Invariant Chain-derived Peptides to Interact with Many Major Histocompatibility Complex-Class II Molecules," <i>J. Exp. Med.</i> 181: 527-536 (1995).
1	C170	Martin, R.M. and Lew, A.M., "Is IgG2a a Good Th1 Marker in Mice?" <i>Immunol. Today</i> 19:49 (1998).
1	C171	Müller, H.M., <i>et al.</i> , "Thrombospondin Related Anonymous Protein (TRAP) of <i>Plasmodium Falciparum</i> in Parasite-Host Cell Interactions," <i>Parassitologia</i> 35(Suppl.): 69-72 (1993).
1	C172	Narvaiza, I., <i>et al.</i> , Intratumoral Coinjection of Two Adenoviruses, One Encoding the Chemokine IFN- $\gamma$ -Inducible Protein-10 and Another Encoding IL-12, Results in Marked Antitumoral Synergy," <i>J. Immunol.</i> 164(6): 3112-3122 (2000).
1	C173	Ojcius, D. M., <i>et al.</i> , "Is Antigen Processing Guided by Major Histocompatibility Complex Molecules?," <i>FASEB J.</i> , 8: 974-978 (1994).
1	C174	Okuda, K., <i>et al.</i> , "Induction of Potent Humoral and Cell-Mediated Immune Responses Following Direct Injection of DNA Encoding the HIV Type 1 <i>env</i> and <i>rev</i> Gene Products," <i>Aids Res. Hum. Retroviruses</i> 11(8): 933-943 (1995).
1	C175	Plebanski, M., <i>et al.</i> , "Protection from <i>Plasmodium berghei</i> Infection by Priming to a Single CTL Epitope with Vaccine Carriers that do not Require Adjuvants," <i>Immunol. Lett.</i> , 56/1-3: 425 (1997) (Abstract No. P.4.05.08).
1	C176	Ramirez, J.C., <i>et al.</i> , "Biology of Attenuated Modified Vaccinia Virus Ankara Recombinant Vector in Mice: Virus Fate and Activation of B- and T-Cell Immune Responses in Comparison with the Western Reserve Strain and Advantages as a Vaccine," <i>J. Virol.</i> 74(2): 923-933 (2000).
1	C177	Reusser, P., <i>et al.</i> , "Cytomegalovirus-Specific T-Cell Immunity in Recipients of Autologous Peripheral Blood Stem Cell or Bone Marrow Transplants," <i>Blood</i> , 89(10): 3873-3879 (1997).
1	C178	Romero, P., <i>et al.</i> , "Cloned Cytotoxic T Cells Recognize an Epitope in the Circumsporozoite Protein and Protect Against Malaria," <i>Nature</i> , 341: 323-326 (1989).
12	C179	Schneider, J., <i>et al.</i> , "DNA Followed by Recombinant Vaccinia Induces Cellular and Humoral Immune Responses Against a Pre-erythrocytic Antigen of <i>Plasmodium falciparum</i> in Chimpanzees," <i>Immunol. Lett.</i> , 56/1-3: 291 (1997) (Abstract No. P.4.01.18).

EXAMINER	DATE CONSIDERED
----------	-----------------

PTO-1449 REPRODUCED  <b>FOURTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION</b>  September 26, 2006  (Use several sheets if necessary)	ATTORNEY DOCKET NO. 3022.1004-000		APPLICATION NO. 10/088,677	
	FIRST NAMED INVENTOR Joerg Schneider		371(C) DATE May 31, 2002	
	EXAMINER Robert A. Zeman	CONFIRMATION NO. 4825	GROUP 1645	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
C180	22	Takada, K., <i>et al.</i> , "Definition of an Epitope on Japanese Encephalitis Virus (JEV) Envelope Protein Recognized by JEV-specific Murine CD8+ Cytotoxic T Lymphocytes," <i>Arch. Virol.</i> , 145: 523-534 (2000).
C181		Vasmatzis, G., <i>et al.</i> , "Computational Determination of Side Chain Specificity for Pockets in Class I MHC Molecules," <i>Mol. Immunol.</i> 33(16): 1231-1239 (1996).
C182		Whitton, J.L., <i>et al.</i> , "A "String-of-Beads" Vaccine, Comprising Linked Minigenes, Confers Protection from Lethal-Dose Virus Challenge," <i>J. Virol.</i> 67(1): 348-352 (1993).
C183		Yang, Y., <i>et al.</i> , "Upregulation of Class I Major Histocompatibility Complex Antigens by Interferon $\gamma$ is Necessary for T-cell-mediated Elimination of Recombinant Adenovirus-infected Hepatocytes <i>In Vivo</i> ," <i>Proc. Natl. Acad. Sci. USA</i> , 92: 7257-7261 (1995).
C184	4	Yellen-Shaw, A.J., <i>et al.</i> , "Point Mutation Flanking a CTL Epitope Ablates In Vitro and In Vivo Recognition of a Full-Length Viral Protein," <i>J. Immunol.</i> 158(7): 3227-3234 (1997).
C185	22	Zhu, M., <i>et al.</i> , "Specific Cytotoxic T-Cell Responses to Human CEA from Patients Immunized with Recombinant Avipox-CEA Vaccine," <i>Clin. Cancer Res.</i> 6: 24-33 (2000).

EXAMINER 	DATE CONSIDERED 5/28/07
---	----------------------------

APPLICATION NO.  
10/088,677

371(C) DATE  
May 31, 2002

CONFIRMATION NO.  
4825

**GROUP  
1645**

**THIRD SUPPLEMENTAL  
INFORMATION DISCLOSURE STATEMENT  
IN AN APPLICATION**

**September 15, 2006**

(Use several sheets if necessary)

SEP 19 2006

U.S. PATENT DOCUMENTS

[illegible]

**EXAMINER**

DATE CONSIDERED

PTO-1449 REPRODUCED  <b>THIRD SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION</b>  September 15, 2006  (Use several sheets if necessary)	ATTORNEY DOCKET NO. 3022.1004-000		APPLICATION NO. 10/088,677	
	FIRST NAMED INVENTOR Joerg Schneider		371(C) DATE May 31, 2002	
	EXAMINER Robert A. Zeman		CONFIRMATION NO. 4825	GROUP 1645

FOREIGN PATENT DOCUMENTS						
		DOCUMENT NUMBER Country Code-Number-Kind Code (if known)	DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT	TRANSLATION YES NO	
22	B6	WO 93/03145	02-18-1993	Virogenetics Corporation		
	B7	WO 96/26271 A1	08-29-1996	Therion Biologics Corporation and The United States Government, represented by The Department of Health and Human Services		
	B8	WO 98/04728 A1	02-05-1998	Therion Biologics Corporation and United States Government, as represented by The Department of Health and Human Services		
	B9	WO 01/85932 A2	11-15-2001	Aventis Pasteur Limited and Ludwig Institute for Cancer Research		
	B10	WO 02/068654 A2	09-06-2002	Centro de Ingenieria Genetica y Biotecnologia		X
22	B11	EP 0 517 292 B1	02-02-2000	Dimminaco AG		X

EXAMINER	DATE CONSIDERED
----------	-----------------

PTO-1449 REPRODUCED  <b>THIRD SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION</b>  September 15, 2006  (Use several sheets if necessary)	ATTORNEY DOCKET NO. 3022.1004-000		APPLICATION NO. 10/088,677	
	FIRST NAMED INVENTOR Joerg Schneider		371(C) DATE May 31, 2002	
	EXAMINER Robert A. Zeman	CONFIRMATION NO. 4825	GROUP 1645	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
C32	C32	Ada, G., "Do Cytotoxic T Lymphocytes Clear Some HIV/SIV Infections?," <i>J. Med. Primatol.</i> 25(3):158-162 (1996).
C33	C33	Afonso, C.L., <i>et al.</i> , "The Genome of Fowlpox Virus," <i>J. Virol.</i> 74(8):3815-3831 (2000).
C34	C34	Aidoo, M., <i>et al.</i> , "Recombinant Vaccinia Viruses for the Characterization of <i>Plasmodium falciparum</i> -specific Cytotoxic T Lymphocytes: Recognition of Processed Antigen Despite Limited Re-Stimulation Efficacy," <i>Intl. Immunol.</i> 9(5):731-737 (1997).
C35	C35	Aidoo, M., <i>et al.</i> , "Identification of Conserved Antigenic Components for a Cytotoxic T Lymphocyte-inducing Vaccine Against Malaria," <i>Lancet</i> 345(8956):1003-1007 (1995).
C36	C36	Allsopp, C.E.M., <i>et al.</i> , "Comparison of Numerous Delivery Systems for the Induction of Cytotoxic T Lymphocytes by Immunization," <i>Eur. J. Immunol.</i> 26:1951-1959 (1996).
C37	C37	Blanchard, T.J., <i>et al.</i> , "Modified Vaccinia Virus Ankara Undergoes Limited Replication in Human Cells and Lacks Several Immunomodulatory Proteins: Implications for Use as a Human Vaccine," <i>J. Gen. Virol.</i> 79:1159-1167 (1998).
C38	C38	Blanchard, T., <i>et al.</i> , "Future Vaccines for HIV," <i>Lancet</i> 348(9043):1741 (1996).
C39	C39	Boulanger, D., <i>et al.</i> , "Morphogenesis and Release of Fowlpox Virus," <i>J. Gen. Virol.</i> 81:675-687 (2000).
C40	C40	Boulanger, D., <i>et al.</i> , "The 131-Amino-Acid Repeat Region of the Essential 39-Kilodalton Core Protein of Fowlpox Virus FP9, Equivariant to Vaccinia Virus A4L Protein, Is Nonessential and Highly Immunogenic," <i>J. Virol</i> 72(1):170-179 (1998).
C41	C41	Boursnell, M.E.G., <i>et al.</i> , "A Fowlpox Virus Vaccine Vector with Insertion Sites in the Terminal Repeats: Demonstration of its Efficacy Using the Fusion Gene of Newcastle Disease Virus," <i>Vet. Microbiol.</i> 23:305-316 (1990).
C42	C42	Boursnell, M.E.G., <i>et al.</i> , "Insertion of the Fusion Gene from Newcastle Disease Virus into a Non-essential Region in the Terminal Repeats of Fowlpox Virus and Demonstration of Protective Immunity Induced by the Recombinant," <i>J. Gen. Virol.</i> 71:621-628 (1990).

EXAMINER	DATE CONSIDERED
----------	-----------------

PTO-1449 REPRODUCED  <b>THIRD SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION</b>  September 15, 2006  (Use several sheets if necessary)	ATTORNEY DOCKET NO. 3022.1004-000		APPLICATION NO. 10/088,677	
	FIRST NAMED INVENTOR Joerg Schneider		371(C) DATE May 31, 2002	
	EXAMINER Robert A. Zeman	CONFIRMATION NO. 4825	GROUP 1645	

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

22	C43	Boyle, D.B. and Heine, H.G., "Recombinant Fowlpox Virus Vaccines for Poultry," <i>Immunol. Cell Biol.</i> 71:391-397 (1993).
	C44	Boyle, D.B., <i>et al.</i> , "Comparison of Field and Vaccine Strains of Australian Fowlpox Viruses," <i>Arch. Virol.</i> 142:737-748 (1997).
	C45	Brooks, J.V., <i>et al.</i> , "Boosting Vaccine for Tuberculosis," <i>Infect. Immun.</i> 69(4): 2714-2717 (2001).
	C46	Brossart, P., <i>et al.</i> , "Virus-Mediated Delivery of Antigenic Epitopes into Dendritic Cells as a Means to Induce CTL," <i>J. Immunol.</i> 158:3270-3276 (1997).
	C47	Campbell, J.I.A., <i>et al.</i> , "Tandem Repeated Sequences within the Terminal Region of the Fowlpox Virus Genome," <i>J. Gen. Virol.</i> 70:145-154 (1989).
	C48	Carroll, M.W., <i>et al.</i> , "Highly Attenuated Modified Vaccinia Virus Ankara (MVA) as an Effective Recombinant Vector: A Murine Tumor Model," <i>Vaccine</i> 15(4):387-394 (1997).
	C49	Carter, B.J., <i>et al.</i> , "Gene Therapy as Drug Development," <i>Mol. Therapy</i> 1(3):211-212 (2000).
	C50	Carvalho, L.J.M., <i>et al.</i> , "Malaria Vaccine: Candidate Antigens, Mechanisms, Constraints and Prospects," <i>Scand. J. Immunol.</i> 56:327-343 (2002).
	C51	Castelli, C., <i>et al.</i> "Mass Spectrometric Identification of a Naturally Processed Melanoma Peptide Recognized by CD8 <sup>+</sup> Cytotoxic T Lymphocytes," <i>J. Exp. Med.</i> 181:363-368 (1995).
	C52	Conry, R.M., <i>et al.</i> , "Safety and Immunogenicity of a DNA Vaccine Encoding Carcinoembryonic Antigen and Hepatitis B Surface Antigen in Colorectal Carcinoma Patients," <i>Clin. Cancer Res.</i> 8:2782-2787 (2002).
A	C53	Coupar, B.E.H., <i>et al.</i> , "Restriction Endonuclease Mapping of the Fowlpox Virus Genome," <i>Virology</i> 179:159-167 (1990).
B	C54	Dale, C.J., <i>et al.</i> , "Induction of HIV-1-Specific T-Helper Responses and Type 1 Cytokine Secretion Following Therapeutic Vaccination of Macaques with a Recombinant Fowlpoxvirus Co-expressing Interferon-Gamma," <i>J. Med. Primatol.</i> 29:240-247 (2000).

EXAMINER	DATE CONSIDERED
----------	-----------------



PTO-1449 REPRODUCED  <b>THIRD SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION</b>  September 15, 2006  (Use several sheets if necessary)	ATTORNEY DOCKET NO. 3022.1004-000		APPLICATION NO. 10/088,677	
	FIRST NAMED INVENTOR Joerg Schneider		371(C) DATE May 31, 2002	
	EXAMINER Robert A. Zeman	CONFIRMATION NO. 4825	GROUP 1645	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
B2	C55	Davis, H.L., <i>et al.</i> , "DNA-Mediated Immunization to Hepatitis B Surface Antigen: Longevity of Primary Response and Effect of Boost," <i>Vaccine</i> 14(9):910-915 (1996).
	C56	Denis, O., <i>et al.</i> , "Vaccination with Plasmid DNA Encoding Mycobacterial Antigen 85A Stimulates a CD4+ and CD8+ T-Cell Epitopic Repertoire Broader than that Stimulated by <i>Mycobacterium tuberculosis</i> H37Rv Infection," <i>Infect. Immun.</i> 66(4):1527-1533 (1998).
	C57	Doolan, D.L., <i>et al.</i> , "Circumventing Genetic Restriction of Protection against Malaria with Multigene DNA Immunization: CD8+ T Cell-, Interferon $\gamma$ -, and Nitric Oxide-Dependent Immunity," <i>J. Exp. Med.</i> 183(4):1739-1746 (1996).
	C58	Doolan, D.L. and Hoffman, S.L., "The Complexity of Protective Immunity Against Liver-Stage Malaria," <i>J. Immunol.</i> 165(3):1453-1462 (2000).
	C59	Drexler, I., <i>et al.</i> , "Highly Attenuated Modified Vaccinia Virus Ankara Replicates in Baby Hamster Kidney Cells, a Potential Host for Virus Propagation, but not in Various Human Transformed and Primary Cells," <i>J. Gen. Virol.</i> 79:347-352 (1998).
	C60	Egan, M.A., <i>et al.</i> , "Induction of Human Immunodeficiency Virus Type 1 (HIV-1)-Specific Cytolytic T Lymphocyte Responses in Seronegative Adults by a Nonreplicating, Host-Range-Restricted Canarypox Vector (ALVAC) Carrying the HIV-1 <sub>MN</sub> env Gene," <i>J. Infect. Dis.</i> 171:1623-1627 (1995).
	C61	Franchini, G., <i>et al.</i> , "Highly Attenuated HIV Type 2 Recombinant Poxviruses, but not HIV-2 Recombinant <i>Salmonella</i> Vaccines, Induce Long-lasting Protection in Rhesus Macaques," <i>AIDS Res. Hum. Retroviruses</i> 11(8):909-920 (1995).
	C62	Fuller, D.H., <i>et al.</i> , "Enhancement of Immunodeficiency Virus-Specific Immune Responses in DNA-immunized Rhesus Macaques," <i>Vaccine</i> 15(8):924-926 (1997).
	C63	Fuller, D.H., <i>et al.</i> , "Gene Gun-Based Nucleic Acid Immunization Alone or in Combination with Recombinant Vaccinia Vectors Suppresses Virus Burden in Rhesus Macaques Challenged with a Heterologous SIV," <i>Immunol. Cell Biol.</i> 75(4):389-396 (1997).
R2	C64	Gallimore, A., <i>et al.</i> , "Early Suppression of SIV Replication By CD8+ <i>nef</i> -specific Cytotoxic T Cells in Vaccinated Macaques," <i>Nature Med.</i> 1(11):1167-1173 (1995).

EXAMINER	DATE CONSIDERED
----------	-----------------



<b>PTO-1449 REPRODUCED</b>  <b>THIRD SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION</b>  <b>September 15, 2006</b>  (Use several sheets if necessary)	<b>ATTORNEY DOCKET NO.</b> 3022.1004-000		<b>APPLICATION NO.</b> 10/088,677	
	<b>FIRST NAMED INVENTOR</b> Joerg Schneider		<b>371(C) DATE</b> May 31, 2002	
	<b>EXAMINER</b> Robert A. Zeman	<b>CONFIRMATION NO.</b> 4825	<b>GROUP</b> 1645	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
R2	C65	Greenspan, N.S. and DiCera, E., "Defining Epitopes: It's not as Easy as it Seems," <i>Nature Biotechnol.</i> 17:936-937 (1999).
	C66	Grosenbach, D.W., <i>et al.</i> , "Synergy of Vaccine Strategies to Amplify Antigen-specific Immune Responses and Antitumor Effects," <i>Cancer Res.</i> 61:4497-4505 (2001).
	C67	Hanke, T., <i>et al.</i> , "DNA Multi-CTL Epitope Vaccines for HIV and <i>Plasmodium falciparum</i> : Immunogenicity in Mice," <i>Vaccine</i> 16(4):426-435 (1998).
	C68	Hertig, C., <i>et al.</i> , "Field and Vaccine Strains of Fowlpox Virus Carry Integrated Sequences from the Avian Retrovirus, Reticuloendotheliosis Virus," <i>Virol.</i> 235:367-376 (1997).
	C69	Hill, A.V.S., <i>et al.</i> , "Common West African HLA Antigens are Associated with Protection from Severe Malaria," <i>Nature</i> 352(6336):595-600 (1991).
	C70	Hill, A.V.S., <i>et al.</i> , "DNA-Based Vaccines for Malaria: a Heterologous Prime-Boost Immunisation Strategy," <i>Dev. Biol.</i> 104:171-179 (2000).
	C71	Hirsch, V.M., <i>et al.</i> , "Patterns of Viral Replication Correlate with Outcome in Simian Immunodeficiency Virus (SIV)-Infected Macaques: Effect of Prior Immunization with a Trivalent SIV Vaccine in Modified Vaccinia Virus Ankara," <i>J. Virol.</i> 70(6):3741-3752 (1996).
	C72	HIV CTL Epitopes Table 2: p24. [online], December 1996. Retrieved from the Internet <URL:http://hiv-web.lanl.gov/content/immunology/pdf/1996/CTL/TABLES/p24.pdf>.
	C73	HIV CTL Epitopes Table 3: p24 [online], December 1999. Retrieved from the Internet <URL:http://hiv-web.lanl.gov/content/immunology/pdf/1999/1/tables/p24.pdf>.
	C74	HIV CTL Epitopes Table 4: Pol [online], December 1997. Retrieved from the Internet <URL:http://hiv-web.lanl.gov/content/hiv-db/immunology/PDF/1997/CTL/tables/pol.pdf>.
	C75	HIV CTL Epitopes Table 6: gp120. [online], December 1996. Retrieved from the Internet <URL:http://hiv-web.lanl.gov/content/immunology/pdf/1996/CTL/TABLES/gp120.pdf>.
R2	C76	HIV CTL Epitopes Table 7: gp41. [online], December 1996. Retrieved from the Internet <URL:http://hiv-web.lanl.gov/content/immunology/pdf/1996/CTL/TABLES/gp41.pdf>.

<b>EXAMINER</b>	<b>DATE CONSIDERED</b>
-----------------	------------------------

PTO-1449 REPRODUCED  <b>THIRD SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION</b>  September 15, 2006  (Use several sheets if necessary)	ATTORNEY DOCKET NO. 3022.1004-000		APPLICATION NO. 10/088,677	
	FIRST NAMED INVENTOR Joerg Schneider		371(C) DATE May 31, 2002	
	EXAMINER Robert A. Zeman	CONFIRMATION NO. 4825	GROUP 1645	

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

12	C77	HIV CTL Epitopes Table 8: Nef. [online], December 1996. Retrieved from the Internet <URL:http://hiv-web.lanl.gov/content/immunology/pdf/1996/CTL/TABLES/nef.pdf>.
1	C78	Holder, A., <i>et al.</i> , "Falciparum Malaria MSP1 Workshop: Progress toward MSP1 Vaccine Development and Testing," <i>Malaria Vaccine Initiative at PATH</i> : 1-30 (2000).
	C79	Huygen, K., <i>et al.</i> , "Immunogenicity and Protective Efficacy of a Tuberculosis DNA Vaccine," <i>Nature Med.</i> 2(8): 893-898 (1996).
	C80	Irvine, K.R., <i>et al.</i> , "Route of Immunization and the Therapeutic Impact of Recombinant Anticancer Vaccines," <i>J. Natl. Cancer Inst.</i> 89(5):390-392 (1997).
	C81	Irvine, K., <i>et al.</i> , "Comparison of a CEA-Recombinant Vaccinia Virus, Purified CEA, and an Anti-Idiotypic Antibody Bearing the Image of a CEA Epitope in the Treatment and Prevention of CEA-Expressing Tumors," <i>Vaccine Res.</i> 2(2):79-94 (1993).
	C82	Johnson, R.P., <i>et al.</i> , "Induction of a Major Histocompatibility Complex Class I-Restricted Cytotoxic T-Lymphocyte Response to a Highly Conserved Region of Human Immunodeficiency Virus Type 1 (HIV-1) gp120 in Seronegative Humans Immunized with a Candidate HIV-1 Vaccine," <i>J. Virol.</i> 68(5):3145-3153 (1994).
	C83	Kent, S.J., <i>et al.</i> , "A Recombinant Avipoxvirus HIV-1 Vaccine Expressing Interferon-gamma is Safe and Immunogenic in Macaques," <i>Vaccine</i> 18:2250-2256 (2000).
	C84	Kent, S.J., <i>et al.</i> , "Analysis of Cytotoxic T Lymphocyte Responses to SIV Proteins in SIV-Infected Macaques Using Antigen-Specific Stimulation with Recombinant Vaccinia and Fowl Poxviruses," <i>AIDS Res. Hum. Retroviruses</i> 10(5):551-560 (1994).
1	C85	Laidlaw, S.M. and Skinner, M.A., "Comparison of the Genome Sequence of FP9, an attenuated, tissue culture-adapted European strain of <i>Fowlpox virus</i> , with those of virulent American and European viruses," <i>J. Gen. Virol.</i> 85:305-322 (2004).
12	C86	Laidlaw, S.M., <i>et al.</i> , "Fowlpox Virus Encodes Nonessential Homologs of Cellular Alpha-SNAP, PC-1, and an Orphan Human Homolog of a Secreted Nematode Protein," <i>J. Virol.</i> 72(8):6742-6751 (1998).

EXAMINER	DATE CONSIDERED
----------	-----------------

<b>PTO-1449 REPRODUCED</b>  <b>THIRD SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION</b>  <b>September 15, 2006</b>  (Use several sheets if necessary)	ATTORNEY DOCKET NO. 3022.1004-000		APPLICATION NO. 10/088,677	
	FIRST NAMED INVENTOR Joerg Schneider		371(C) DATE May 31, 2002	
	EXAMINER Robert A. Zeman	CONFIRMATION NO. 4825	GROUP 1645	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
R2	C87	Lalvani, A., <i>et al.</i> , "An HLA-based Approach to the Design of a CTL-Inducing Vaccine Against <i>Plasmodium falciparum</i> ," <i>Res. Immunology</i> 145(6):461-468 (1994).
1	C88	Lanar, D.E., <i>et al.</i> , "Attenuated Vaccinia Virus-Circumsporozoite Protein Recombinants Confer Protection against Rodent Malaria," <i>Infect. Immun.</i> 64(5):1666-1671 (1996).
	C89	Layton, G.T., <i>et al.</i> , "Induction of Single and Dual Cytotoxic T-Lymphocyte Responses to Viral Proteins in Mice Using Recombinant Hybrid Ty-Virus-Like Particles," <i>Immunology</i> 87(2):171-178 (1996).
	C90	Leong, K.H., <i>et al.</i> , "Selective Induction of Immune Responses by Cytokines Coexpressed in Recombinant Fowlpox Virus," <i>J. Virol.</i> 68(12):8125-8130 (1994).
	C91	Leong, K.H., <i>et al.</i> , "Generation of Enhanced Immune Responses by Consecutive Immunization with DNA and Recombinant Fowl Pox Vectors," <i>Vaccines</i> 95:327-331 (1995).
	C92	Limbach, K.J. and Paoletti, E., "Non-Replicating Expression Vectors: Application in Vaccine Development and Gene Therapy," <i>Epidemiol. Infect.</i> 116:241-256 (1996).
	C93	Mahnel, <i>et al.</i> , "Experiences with Immunization Against Orthopox Viruses of Humans and Animals Using Vaccine Strain MVA," <i>Berliner Und Munchener Tierarztliche Wochenschrift</i> 107(8):253-256 (1994) ABSTRACT ONLY
	C94	Mayr, A. and Malicki, K., "Attenuierung von virulentem Hühnerpockenvirus in Zellkulturen und Eigenschaften des attenuierten Virus," <i>Zbl. Vet. Med. B</i> B13:1-13 (1966).
	C95	Meyer, H., <i>et al.</i> , "Mapping of Deletions in the Genome of the Highly Attenuated Vaccinia Virus MVA and their Influence on Virulence," <i>J. Gen. Virol.</i> 72:1031-1038 (1991).
4	C96	Moorthy, V.S., <i>et al.</i> , "Safety of DNA and Modified Vaccinia Virus Ankara Vaccines Against Liver-Stage <i>P. falciparum</i> Malaria in Non-Immune Volunteers," <i>Vaccine</i> 21(17-18):1995-2002 (2003).
R2	C97	Moorthy, V. and Hill, A.V.S., "Malaria Vaccines," <i>Br. Med. Bull.</i> 62:59-72 (2002).

EXAMINER	DATE CONSIDERED
----------	-----------------

PTO-1449 REPRODUCED  <b>THIRD SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION</b>  September 15, 2006  (Use several sheets if necessary)	ATTORNEY DOCKET NO. 3022.1004-000		APPLICATION NO. 10/088,677	
	FIRST NAMED INVENTOR Joerg Schneider		371(C) DATE May 31, 2002	
	EXAMINER Robert A. Zeman	CONFIRMATION NO. 4825	GROUP 1645	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
82	C98	Moreno, A., <i>et al.</i> , "Cytotoxic CD4+ T Cells From a Sporozoite-Immunized Volunteer Recognize the <i>Plasmodium falciparum</i> CS Protein," <i>Int. Immunol.</i> 3(10):997-1003 (1991).
	C99	Moss, B., "Genetically Engineered Poxviruses for Recombinant Gene Expression, Vaccination, and Safety," <i>Proc. Natl. Acad. Sci. USA</i> 93:11341-11348 (1996).
	C100	Moss, B., <i>et al.</i> , "Host Range Restricted, Non-Replicating Vaccinia Virus Vectors as Vaccine Candidates." In <i>Novel Strategies in Design and Production of Vaccines</i> , S.Cohen <i>et al.</i> , eds. (NY:Plenum Press), pp. 7-13 (1996).
	C101	Müller, H.-M., <i>et al.</i> , "Thrombospondin Related Anonymous Protein (TRAP) of <i>Plasmodium falciparum</i> Binds Specifically to Sulfated Glycoconjugates and to HepG2 Hepatoma Cells Suggesting a Role for this Molecule in Sporozoite Invasion of Hepatocytes," <i>EMBO J.</i> 12(7):2881-2889 (1993).
	C102	Murata, K., <i>et al.</i> , "Characterization of <i>in Vivo</i> Primary and Secondary CD8 <sup>+</sup> T Cell Responses Induced by Recombinant Influenza and Vaccinia Viruses," <i>Cell. Immunol.</i> 173(1):96-107 (1996).
	C103	Nardin, E.H. and Nussenzweig, R.S., "T Cell Responses to Pre-Erythrocytic Stages of Malaria: Role in Protection and Vaccine Development Against Pre-Erythrocytic Stages," <i>Annu. Rev. Immunol.</i> 11:687-727 (1993).
	C104	NCBI Accession No. AF198100, "Fowlpox virus, complete genome," [online], March 2000. [retrieved on 2006-09-14] Retrieved from the Internet <URL:http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=7271507>.
	C105	Ohminami, H., <i>et al.</i> , "HLA Class I-Restricted Lysis of Leukemia Cells by a CD8 <sup>+</sup> Cytotoxic T-Lymphocyte Clone Specific for WT1 Peptide," <i>Blood</i> 95(1):286-293 (2000).
	C106	Paoletti, E., "Applications of Pox Virus Vectors to Vaccination: An Update," <i>Proc. Natl. Acad. Sci. USA</i> 93:11349-11353 (1996).
82	C107	Pialoux, G., <i>et al.</i> , "A Prime-Boost Approach to HIV Preventive Vaccine Using a Recombinant Canarypox Virus Expressing Glycoprotein 160 (MN) Followed by a Recombinant Glycoprotein 160 (MN/LAI)," <i>AIDS Res. Hum. Retroviruses.</i> 11(3):373-381 (1995).

EXAMINER	DATE CONSIDERED
----------	-----------------

<b>PTO-1449 REPRODUCED</b>  <b>THIRD SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION</b>  <b>September 15, 2006</b>  (Use several sheets if necessary)	ATTORNEY DOCKET NO. 3022.1004-000		APPLICATION NO. 10/088,677	
	FIRST NAMED INVENTOR Joerg Schneider		371(C) DATE May 31, 2002	
	EXAMINER Robert A. Zeman	CONFIRMATION NO. 4825	GROUP 1645	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
27	C108	Pollitt, E., <i>et al.</i> , "Nucleotide Sequence of the 4.3 kbp BamHI-N Fragment of Fowlpox Virus FP9," <i>Virus Genes</i> 17(1):5-9 (1998).
	C109	Qingzhong, Y., <i>et al.</i> , "Protection Against Turkey Rhinotracheitis Pneumovirus (TRTV) Induced by a Fowlpox Virus Recombinant Expressing the TRTV Fusion Glycoprotein (F)," <i>Vaccine</i> 12(6):569-573 (1994).
	C110	Ramarathinam, L., <i>et al.</i> , "Multiple Lineages of Tumors Express a Common Tumor Antigen, P1A, but they are not Cross-Protected," <i>J. Immunol.</i> 155: 5323-5329 (1995).
	C111	Rimoldi, D., <i>et al.</i> , "Efficient Simultaneous Presentation of NY-ESO-1/LAGE-1 Primary and Nonprimary Open Reading Frame-Derived CTL Epitopes in Melanoma," <i>J. Immunol.</i> , 165:7253-7261 (2000).
	C112	Rodrigues, M., <i>et al.</i> , "Influenza and Vaccinia Viruses Expressing Malaria CD8 <sup>+</sup> T and B Cell Epitopes," <i>J. Immunol.</i> 153(10):4636-4648 (1994).
	C113	Rodriguez, D., <i>et al.</i> , "Regulated Expression of Nuclear Genes by T3 RNA Polymerase and <i>lac</i> Repressor, Using Recombinant Vaccinia Virus Vectors," <i>J. Virol.</i> 64(10):4851-4857 (1990).
	C114	Schödel, F., <i>et al.</i> , "Immunity to Malaria Elicited by Hybrid Hepatitis B Virus Core Particles Carrying Circumsporozoite Protein Epitopes," <i>J. Exp. Med.</i> 180(3):1037-1046 (1994).
	C115	Sedegah, M., <i>et al.</i> , "Protection against Malaria by Immunization with Plasmid DNA Encoding Circumsporozoite Protein," <i>Proc. Natl. Acad. Sci. USA</i> 91(21):9866-9870 (1994).
4	C116	Seguin, M.C., <i>et al.</i> , "Induction of Nitric Oxide Synthase Protects against Malaria in Mice Exposed to Irradiated <i>Plasmodium berghei</i> Infected Mosquitoes: Involvement of Interferon $\gamma$ and CD8 <sup>+</sup> T Cells," <i>J. Exp. Med.</i> 180(1):353-358 (1994).
28	C117	Sequence Alignment of SEQ ID NO: 4 from U.S. Application No. 10/079,167 with Geneseq database ID NO: AAR43245 from WO 93/201103-A. Entry date: May, 1994 Inventor: Elvin, <i>et al.</i>

EXAMINER	DATE CONSIDERED
----------	-----------------

PTO-1449 REPRODUCED  <b>THIRD SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION</b>  September 15, 2006  (Use several sheets if necessary)	ATTORNEY DOCKET NO. 3022.1004-000		APPLICATION NO. 10/088,677	
	FIRST NAMED INVENTOR Joerg Schneider		371(C) DATE May 31, 2002	
	EXAMINER Robert A. Zeman	CONFIRMATION NO. 4825	GROUP 1645	

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

R	C118	Sequence Alignment of SEQ ID NO: 2 from U.S. Application No. 10/079,167 with Geneseq database ID NO: AAR43244 from WO 93/201103-A. Entry date: May, 1994 Inventor: Elvin, <i>et al.</i>
	C119	Sequence Alignment of SEQ ID NO: 6 from U.S. Application No. 10/079,167 with Geneseq database ID NO: AAR43243 from WO 93/201103-A. Entry date: May, 1994 Inventor: Elvin, <i>et al.</i>
	C120	Shaw, I., and Davison, T.F., "Protection From IBDV-induced Bursal Damage by a Recombinant Fowlpox Vaccine, fpIBD1, is Dependent on the Titre of Challenge Virus and Chicken Genotype," <i>Vaccine</i> 18:3230-3241 (2000).
	C121	Skinner, M.A., <i>et al.</i> , "Fowlpox Virus as a Recombinant Vaccine Vector for use in Mammals and Poultry," <i>Expert Rev. Vaccines</i> 4(1):63-76 (2005).
	C122	Somogyi, P., <i>et al.</i> , "Fowlpox Virus Host Range Restriction: Gene Expression, DNA Replication, and Morphogenesis in Nonpermissive Mammalian Cells," <i>Virology</i> 197:439-444 (1993).
	C123	Stoute, J.A., <i>et al.</i> , "A Preliminary Evaluation of a Recombinant Circumsporozoite Protein Vaccine Against <i>Plasmodium falciparum</i> Malaria," <i>N. Engl. J. Med.</i> 336(2):86-91 (1997).
	C124	Sutter, G., <i>et al.</i> , "A Recombinant Vector Derived From the Host Range-Restricted and Highly Attenuated MVA Strain of Vaccinia Virus Stimulates Protective Immunity in Mice to Influenza Virus," <i>Vaccine</i> 12(11):1032-1040 (1994).
	C125	Sutter, G. and Moss, B., "Nonreplicating Vaccinia Vector Efficiently Expresses Recombinant Genes," <i>Proc. Natl. Acad. Sci. USA</i> 89:10847-10851 (1992).
	C126	SYFPEITHI Database, "Find Your Motif," [online], [retrieved on 2006-09-01]. Retrieved from the Internet <URL: <a href="http://www.syfpeithi.de/Scripts/MHCServer.dll/FindYourMotif.htm">http://www.syfpeithi.de/Scripts/MHCServer.dll/FindYourMotif.htm</a> >.
J	C127	Tanghe, A., <i>et al.</i> , "Improved Immunogenicity and Protective Efficacy of a Tuberculosis DNA Vaccine Encoding Ag85 by Protein Boosting," <i>Infect. Immun.</i> 69(5):3041-3047 (2001).
R	C128	Tartaglia, J., <i>et al.</i> , "NYVAC: A Highly Attenuated Strain of Vaccinia Virus," <i>Virology</i> 188(1):217-232 (1992).

EXAMINER	DATE CONSIDERED
----------	-----------------




PTO-1449 REPRODUCED  <b>THIRD SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION</b>  September 15, 2006  (Use several sheets if necessary)	ATTORNEY DOCKET NO. 3022.1004-000		APPLICATION NO. 10/088,677	
	FIRST NAMED INVENTOR Joerg Schneider		371(C) DATE May 31, 2002	
	EXAMINER Robert A. Zeman	CONFIRMATION NO. 4825	GROUP 1645	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
C129	C129	Tartaglia, J., <i>et al.</i> , "Protection of Cats against Feline Leukemia Virus by Vaccination with a Canarypox Virus Recombinant, ALVAC-FL," <i>J. Virol.</i> 67(4):2370-2375 (1993).
C130	C130	Tascon, R.E., <i>et al.</i> , "Vaccination Against Tuberculosis by DNA Injection," <i>Nature Med.</i> 2(8): 888-892 (1996).
C131	C131	Taylor, J. and Paoletti, E., "Fowlpox Virus as a Vector in Non-Avian Species," <i>Vaccine</i> 6:466-468 (1988).
C132	C132	Taylor, J., <i>et al.</i> , "Protective Immunity Against Avian Influenza Induced by Fowlpox Virus Recombinant," <i>Vaccine</i> 6:504-508 (1988).
C133	C133	Taylor, J., <i>et al.</i> , "Recombinant Fowlpox Virus Inducing Protective Immunity in Non-Avian Species," <i>Vaccine</i> 6(6):497-503 (1988).
C134	C134	Thomson, S.A., <i>et al.</i> , "Delivery of Multiple CD8 Cytotoxic T Cell Epitopes by DNA Vaccination," <i>J. Immunol.</i> 160:1717-1723 (1998).
C135	C135	Tsang, K.Y., <i>et al.</i> , "Generation of Human Cytotoxic T Cells Specific for Human Carcinoembryonic Antigen Epitopes From Patients Immunized With Recombinant Vaccinia-CEA Vaccine," <i>J. Natl. Cancer Inst.</i> 87(13):982-990 (1995).
C136	C136	Tsuji, M., <i>et al.</i> , "CD4 <sup>+</sup> Cytolytic T Cell Clone Confers Protection against Murine Malaria," <i>J. Exp. Med.</i> 172(5):1353-1357 (1990).
C137	C137	Tsukamoto, K., <i>et al.</i> , "Dual-Viral Vector Approach Induced Strong and Long-Lasting Protective Immunity against Very Virulent Infectious Bursal Disease Virus," <i>Virology</i> 269(2):257-267 (2000).
C138	C138	Van den Eynde, B. and van der Bruggen, P., "Peptide Database," <i>Cancer Immunity</i> , March 2001, online, retrieved from the Internet on June 23, 2003. <URL: <a href="http://cancerimmunity.org/peptidedatabase/tcellepitopes.htm">http://cancerimmunity.org/peptidedatabase/tcellepitopes.htm</a> >
C139	C139	Walker, B.D., <i>et al.</i> , "Long-term Culture and Fine Specificity of Human Cytotoxic T-Lymphocyte Clones Reactive with Human Immunodeficiency Virus Type 1," <i>Proc. Natl. Acad. Sci. USA</i> 86:9514-9518 (1989).

EXAMINER	DATE CONSIDERED
----------	-----------------

PTO-1449 REPRODUCED  <b>THIRD SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION</b>  September 15, 2006  (Use several sheets if necessary)	ATTORNEY DOCKET NO. 3022.1004-000		APPLICATION NO. 10/088,677	
	FIRST NAMED INVENTOR Joerg Schneider		371(C) DATE May 31, 2002	
	EXAMINER Robert A. Zeman	CONFIRMATION NO. 4825	GROUP 1645	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
C140	Wang, M., et al.,	"Active Immunotherapy of Cancer with a Nonreplicating Recombinant Fowlpox Virus Encoding a Model Tumor-associated Antigen," <i>J. Immunol.</i> 154(9):4685-4692 (1995).
C141	Wang, R., et al.,	"Induction of CD4 <sup>+</sup> T Cell-dependent CD8 <sup>+</sup> Type 1 Responses in Humans by a Malaria DNA Vaccine," <i>Proc. Natl. Acad. Sci. USA</i> 98(19):10817-10822 (2001).
C142	Watson, J.C. and Peter, G.,	"General Immunization Practices," in <i>Vaccines</i> , Plotkin, S.A. and Orenstein, eds., (W.B. Saunders) pp. 47-73 (1999).
C143	Wizel, B., et al.,	"Irradiated Sporozoite Vaccine Induces HLA-B8-Restricted Cytotoxic T Lymphocyte Responses against Two Overlapping Epitopes of the <i>Plasmodium falciparum</i> Sporozoite Surface Protein 2," <i>J. Exp. Med.</i> 182(5):1435-1445 (1995).
C144	Zhu, X., et al.,	"Functions and Specificity of T Cells Following Nucleic Acid Vaccination of Mice Against <i>Mycobacterium tuberculosis</i> Infection," <i>J. Immunol.</i> 158:5921-5926 (1997).
C145	Zorn, E. and Hercend, T.,	"A Natural Cytotoxic T Cell Response in a Spontaneously Regressing Human Melanoma Targets a Neoantigen Resulting from a Somatic Point Mutation," <i>Eur. J. Immunol.</i> 29:592-601 (1999).
C146		

EXAMINER 	DATE CONSIDERED 5/28/07
---	----------------------------